- Fourth quarter and year-end financial results to be released March 9,
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, Feb. 23 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference call on Wednesday, March 9, 2011 at
8:30 a.m. (ET) to discuss its fiscal 2010 fourth quarter and year-end
financial results. Cipher invites all interested parties to
participate. You can join the call by dialing 647-427-7450 or
1-888-231-8191. Please call in 15 minutes prior to the call to secure a line. You will
be put on hold until the conference call begins.
Larry Andrews, President and CEO, will chair the call. A question and
answer session will follow, at which time the operator will direct
participants as to the correct procedure for submitting questions. A
taped replay of the conference call will be available until Wednesday,
March 16, 2011 by calling 416-849-0833 or 1-800-642-1687, reference
A live audio webcast of the conference call will be available through www.cipherpharma.com. Please connect at least 15 minutes prior to the conference call to
ensure adequate time for any software download that may be needed to
hear the webcast. An archived replay of the webcast will be available
for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a commercial-stage drug development company
focused on commercializing novel formulations of successful, currently
marketed molecules using advanced drug delivery technologies. Cipher's
strategy is to in-license products that incorporate proven drug
delivery technologies and advance them through the clinical development
and regulatory approval stages, after which the products are
out-licensed to international partners. Because Cipher's products are
based on proven technology platforms applied to currently marketed
drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The
Company's lead compound is being marketed in the United States by Kowa
Pharmaceuticals America under the label Lipofen®. Cipher's second
product, an extended-release version of the pain reliever tramadol,
received FDA approval in May 2010 and the Company's third product, a
novel formulation of the acne treatment isotretinoin, is in its final
Phase III safety study.
Cipher is listed on the Toronto Stock Exchange under the symbol 'DND'
and has approximately 24 million shares outstanding. For more
information, please visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information: